COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry.
<h4>Background</h4>The COVID-19 pandemic challenges neurologists in counselling patients with multiple sclerosis (pwMS) regarding their risk by SARS-CoV-2 and in guiding disease-modifying treatment (DMT).<h4>Objective</h4>To characterize the prevalence and outcome of COVID-19...
Main Authors: | Gabriel Bsteh, Hamid Assar, Harald Hegen, Bettina Heschl, Fritz Leutmezer, Franziska Di Pauli, Christiane Gradl, Gerhard Traxler, Gudrun Zulehner, Paulus Rommer, Peter Wipfler, Michael Guger, Christian Enzinger, Thomas Berger, AUT-MuSC investigators |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0255316 |
Similar Items
-
Estimating Risk of Multiple Sclerosis Disease Reactivation in Pregnancy and Postpartum: The VIPRiMS Score
by: Gabriel Bsteh, et al.
Published: (2022-01-01) -
Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab—A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry
by: Michael Guger, et al.
Published: (2020-08-01) -
Feasibility of a smartphone app to monitor patient reported outcomes in multiple sclerosis: The haMSter interventional trial
by: Patrick Altmann, et al.
Published: (2022-11-01) -
Predisposing Factors for Sexual Dysfunction in Multiple Sclerosis
by: Patrick Altmann, et al.
Published: (2021-02-01) -
Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MS
by: Tobias Zrzavy, et al.
Published: (2024-04-01)